Chemical Process Intensification
On Demand Webinar

Chemical Process Intensification

On Demand Webinar

Merck's Rapid Decision Making Enabled Through Chemical Process Intensification

Shane Grosser discusses how Merck's Process Development Intensification Laboratory develops new tools and methods to increase the speed and decrease the cost of chemical process development.
Shane T. Grosser, Ph.D. - Merck
35 Minutes
English ,

Within chemical process development, program timing often dictates making informed decisions with limited process understanding, especially in the early clinical delivery space. To facilitate this, the Merck Process Development Intensification Laboratory is tasked with developing tools and methodologies aimed towards acquisition of deeper, more fundamental process understanding in a resource sparing manner. These chemical process development techniques are centrally focused around data intensification, or more specifically, more efficient data capture, data reduction and data analysis enabled by:

  • Process Modeling
  • High Throughput Automation
  • Process Analytical Technologies (PAT)
  • Automated Reactor Implementation
  • Statistically Designed Experimentation and Analysis (DoE)

During this webinar, some of the developed methodologies around data intensification and rapid optimization are presented with examples including:

  1. Optimization of a palladium catalyzed C-O coupling reaction
  2. Risk mitigation studies associated with solids suspension and dissolution across lab and pilot scale execution
  3. Rapid identification of the preferred operating conditions of an aryl ether de-protection reaction on a very aggressive timeline

After receiving a Ph.D. in Chemical Engineering from Carnegie Mellon University in 2007, Dr. Grosser joined Merck’s Chemical Process Development and Commercialization department where he is currently an Associate Principal Scientist within the CPDC Technology Labs.  Since joining CPDC in 2007, Dr. Grosser has experienced a broad range of interesting projects, spanning much of small molecule drug substance development including:  Clinical API manufacture, technology transfer across pilot, commercialization and supply scales, as well as regulatory support for multiple programs.  In addition to multiple project leader assignments, he has also led the department’s Process Modeling Technology Working Group from 2009 to 2014 and has led the Process Development Intensification Laboratory since early 2014.